European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) Four-Week Dosing Schedule For  Adjuvant Treatment Of Adult Patients With Melanoma With Involvement Of Lymph Nodes Or Metastatic Disease Who Have Undergone Complete Resection